TY - JOUR A2 - Ben-Yosef, Rami AU - Johansson, Silvia AU - Åström, Lennart AU - Sandin, Fredrik AU - Isacsson, Ulf AU - Montelius, Anders AU - Turesson，Ingela PY - 2012 DA - 2012/07/08 TI - Hypofractionated质子提高结合体外放疗治疗局限性前列腺癌的SP - 654861六世20 Gy - 2012 AB -质子提高在日常5 Gy分数紧随其后的是体外放射治疗(EBRT) 50 Gy在日常2 Gy分数是278名前列腺癌患者T1b到T4N0M0的癌症53%的患者接受了新辅助雄激素剥夺治疗(N-ADT)。中期随访57个月。低、中、高危患者的5年PSA无进展生存率分别为100%、95%和74%。毒性评估由每次会诊前患者报告的问卷支持。泌尿生殖系统(GU)和胃肠道(GI)毒性的累积概率和精算患病率根据RTOG分类进行介绍。N-ADT对治愈无影响。研究发现，轻度的预处理谷氨酰胺症状是可归因于治疗的谷氨酰胺毒性的强预测因素。 The actuarial prevalence declined over 3 to 5 years for both GU and GI toxicities, indicating slow resolution of epithelial damage to the genitourinary and gastrointestinal tract. Bladder toxicities rather than gastrointestinal toxicities seem to be dose limiting. More than 5-year followup is necessary to reveal any sign of true progressive late side effects of the given treatment. Hypofractionated proton-boost combined with EBRT is associated with excellent curability of localized PC and acceptable frequencies of treatment toxicity. SN - 2090-3111 UR - https://doi.org/10.1155/2012/654861 DO - 10.1155/2012/654861 JF - Prostate Cancer PB - Hindawi Publishing Corporation KW - ER -